

Research and Advocacy Success Metrics

Characteristics

- Interim milestones to long-term success
- Measurable within a year
- Clear and understood by all staff and volunteers
- Objective/able to evaluate if they have been met
- Indicators of successful implementation of JDRF Research and Advocacy strategy

Research and Advocacy Effectiveness Metrics

Artificial Pancreas

- Pivotal outpatient trial of predictive low glucose suspend artificial pancreas system funded and initiated
- Outpatient Treat to Range trial funded and IDE submitted to FDA

Metabolic Control

- At least one T1D trial to improve glucose control with drug approved for T2D initiated with JDRF assistance

Beta Cell Survival/Function

- At least one trial funded and initiated with drug approved for another disorder to enhance beta cell survival in T1D

Encapsulation

- Viacyte files IND with FDA (or equivalent) for human proof of concept trial of encapsulated islet progenitors
- Encapsulation Consortium launches at least two collaborative projects to develop 2nd and 3rd generation encapsulation approaches

Research and Advocacy Effectiveness Metrics

Beta Cell Specific Immune Tolerance

- Recruitment completed and 80% reach primary endpoint in proinsulin peptide new onset T1D clinical trial
- Advance at least one nanoparticle program to the next phase of development with industry

T1D Secondary Prevention

- Trial initiated to demonstrate slowing progression in at-risk for T1D

Co-funding T1D Research

- JDRF stimulates \$5M in industry partner funding
- Other non-profits fund at least \$3M research with JDRF

Special Diabetes Program

- Congress enacts \$150 million extension of the Special Diabetes Program at the National Institutes of Health

Research and Advocacy Effectiveness Metrics

New Consortium/ Partnerships

- JDRF creates at least one new consortium program focused on discovery and/or development of biomarkers for T1D

Optimizing Existing T1D Research Networks

- NIH adopts JDRF recommendations for improved effectiveness of TrialNet

Regulatory Science

- Formal advocacy position formulated for influencing FDA and professional societies on staging and diagnosis of T1D in the at-risk setting